Prevalence and Susceptibility Pattern of Extended Spectrum β-lactamases Producing In Escherichia coli and Klebsiella pneumoniae at Maharat Nakhon Ratchasima Hospital, Thailand
Article Sidebar
Main Article Content
Abstract
The ESBL-producing Escherichia coli and Klebsiella pneumoniae are important pathogens which cause infectious diseases. The prevalence of these organisms have increased in trend worldwide. In addition, the ESBL-producing bacteria are resistant to multiple antibiotics. Thus, this study was aimed to determine the prevalence and susceptibility pattern of ESBLs-producing E. coli and K. pneumoniae in patients at Maharat Nakhon Ratchasima Hospital, Thailand. A total of 22,865 isolates of E. coli and 26,919 isolates of K. pneumoniae were isolated from patients at Maharat Nakhon Ratchasima Hospital from 2010 to 2014. The ESBL-producing strains were found in 9,395 (41.1 %) isolates of E. coli and 12,152 (45.1 %) isolates of K. pneumoniae. Furthermore, the ESBL-producing E. coli were most commonly found in urine (49.7 %), followed by pus (19.1 %), blood (15.2 %) and sputum (9.6 %). The ESBL-producing K. pneumoniae isolates were most commonly found in sputum and then urine, pus and blood. The percentages are 69.8, 13.8, 6.7 and 5.8 percent, respectively. The susceptibility pattern of these organisms were found susceptible to amikacin, netilmicin, cefoxitin, augmentin, gentamicin and trimethoprim-sulfamethoxazole but these organisms were resistant to ampicillin, cefazolin, cefuroxime and ceftriaxone. However, this study found that the ESBL-producing E. coli and K. pneumoniae were susceptible to ertapenem, imipinem and meropenem.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Saonuam P, Hiransuthikul N, Suankratay C, Malathum K, Danchaivijitr S. Risk factors for nosocomial infections caused by extended-spectrum β-lactamase producing Escherichia coli or Klebsiella pneumonia in Thailand. Asian Biomedicine 2008; 2: 485-91.
Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1991; 35: 1697-704.
Philippon A, Ben Redjeb S, Ben Hassen A, Fournier G. Epidemiology of extended spectrum β-lactamases. Infection 1989; 17: 347-54.
Livermore DM. Beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
Pitout JDD, Laupland KB. Extended-spectrum β- lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006; 27: 1226-32.
Winokur PL, Canton R, Casellas J-M, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific Region. Clin Infect Dis 2001; 32(Suppl 2): S94-S103.
Bauernfeind A, H๖rl G. Novel R-factor borne β-lactamase of Escherichia coli conferring resistance to cephalosporins. Infection 1987; 15: 257-9.
Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-7.
Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
Eliopoulos GM, Bush K. New β-lactamases in gramnegative bacteria: Diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-9.
Kirby WM, Yoshihara GM, Sundsted KS, Warren JH. Clinical usefulness of a single disc method for antibiotic sensitivity testing. Antibiot Annu 1956; 1: 892-7.
Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, et al. Prevalence and spread of extended- spectrum β-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008; 14: 144-53.
Villegas MV, Blanco MG, Sifuentes-Osornio J, Rossi F. Increasing prevalence of extended-spectrum-beta lactamase among Gram-negative bacilli in Latin America 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Brazilian J Infect Dis 2011; 15: 34-9.
Rossi F. In vitro susceptibilities of aerobic and facultatively anaerobic Gramnegative bacilli isolated from patients with intraabdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resis-tance Trends). J Antimicrob Chemother 2006; 58: 205-10.
Falagas ME, Karageorgopoulos DE. Extended-spectrum β-lactamase-producing organisms. J Hosp Infect 2009; 73: 345-54.
Hawkey PM. Prevalence and clonality of extend ed-spectrum β-lactamases in Asia. Clin Microbiol Infect 2008; 14: 159-65.
Jan IS, Hsueh PR, Teng LJ, Ho SW, Luh KT. Antimicrobial susceptibility testing for Klebsiella pneumonia isola-tes resistant to extended-spectrum beta-lactam antibiotics. J Formos Med Assoc 1998; 97: 661-6.
Kawakami S, Ono Y, Yamamoto M, Matumura M, Okamoto R, Inoue M, et al. Extended-spectrum beta lacta-mase (ESBL) produced by Escherichia coli and Klebsiella pneumoniae isolated from Teikyou University Hospital the first report. Kansenshogaku Zasshi 1999; 73: 1110-5.
Pai H. The characteristics of extended-spectrum betalactamases in Korean isolates of Enterobacteriaceae. Yonsei Med J 1998; 39: 514-9.
Chayakulkeeree M, Junsriwong P, Keerasuntonpong A, Tribuddharat C, Thamlikitkul V. Epidemiology of exten-ded-spectrum beta-lactamase producing gram-negative bacilli at Siriraj Hospital, Thailand, 2003. Southeast Asian J Trop Med Public Health 2005; 36: 1503-9.
Jitsurong S, Yodsawat J. Prevalence of extendedspec-trum beta-lactamases (ESBLs) produced in blood isolates of gram-negative bacteria in a teaching hospital in sou-thern Thailand. Southeast Asian J Trop Med Public Health 2006; 37: 131-5.
Ingviya N, Hortiwakul R, Chayakul P, Thamjarung B. Prevalence and susceptibility patterns of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta lactamases in Songklanagarind Hospital, Thailand. J Infect Dis Antimicrob Agents 2003; 20: 127-34.
Chaikittisuk N, Munsrichoom A. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children at Queen Sirikit National Institute of Child Health. J Infect DisAntimicrob Agents 2007; 24: 107-15.
Karaket C. The prevalence of extended-spectrum β-lactamase producing K. pneumoniae and E. coli at Chiang-kham Hospital, Thailand (2011-2012). Phichit Hosp J 2012-2013; 28: 21-30.
Amornthipayawong D, Jittrawongpan P, Nontasit W, Mongkolwisut P, Supajin A. The prevalence of extended-spectrum β-lactamases producing Klebsiella pneumoniae and Escherichia coli isolated from patients attending in Nan Hospital and Community Hospital in Nan province, Thailand (2004-2010). Bull Chiangmai Assoc Med Sci 2011; 44: 169-76.
Tunyapanit W, Pruekprasert P. Extended-spectrum beta lactamases in Escherichia coli isolated from patients with community-acquired urinary tract infection at Songklanagarind Hospital, Thailand. J Infect Dis Antimicrob Agents 2006; 23: 51-6.